Intralesional Rituximab for the Treatment of Conjunctival Indolent Lymphoma

PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

December 31, 2011

Primary Completion Date

October 31, 2014

Study Completion Date

October 31, 2019

Conditions
Ocular Adnexal Mucosa-Associated Lymphoid Tissue Lymphoma
Interventions
DRUG

intralesional rituximab

10-20 mg (1-2 ml) rituximab once a week for 4 weeks; followed by 10-20 mg (1-2 ml) rituximab monthly per six months

BIOLOGICAL

supplemental autologous serum

patients in PD or SD during or after administration of 6 doses monthly rituximab will be administered the same dose of intralesional rituximab supplemented by autologous serum

Trial Locations (1)

Unknown

Dip. Oncoematologia - Fondazione Centro San Raffaele del Monte Tabor, Milan

All Listed Sponsors
lead

Andres J. M. Ferreri

OTHER

NCT01514344 - Intralesional Rituximab for the Treatment of Conjunctival Indolent Lymphoma | Biotech Hunter | Biotech Hunter